Off Insulin After Islet Transplant: What One Patient's Clinical Trial Outcome Shows

For decades, people with Type 1 diabetes have heard the same refrain: a cure is five years away. But seeing someone actually stop taking insulin because of a clinical intervention is rare enough to merit serious attention. At the University of Chicago, one study participant achieved insulin independence through a combination approach: islet cell transplantation paired with teplizumab, a drug designed to modulate immune function.

Katie Beth, the patient at the center of this trial, now maintains blood sugar levels that mirror those of a fully functioning pancreas—without requiring daily insulin injections. This outcome represents a meaningful shift in what combination therapies might accomplish for select patients.

The approach combines two distinct interventions. Islet cell transplantation introduces insulin-producing cells from a donor pancreas into the patient's body. Teplizumab works to suppress the immune attack that destroys these transplanted cells—the core problem in Type 1 diabetes.

By pairing cell replacement with immune modulation, the research team aimed to create conditions where transplanted islets could survive and function long-term. In this case, the combination appears to have succeeded.

This outcome is significant but comes with essential caveats. One patient's success in a clinical trial does not establish a cure, nor does it mean the treatment is ready for widespread use. Clinical trials exist to test whether approaches work safely and effectively—outcomes can vary considerably among participants.

Additionally, islet transplantation typically requires ongoing immunosuppression to prevent rejection, which carries its own risks and side effects. The absence of severe transplant complications so far is encouraging but does not guarantee long-term safety or durability.

More data from this trial and other research will be needed to understand how many patients might benefit, how long the effect lasts, and what risks accompany the treatment over time.

This case demonstrates that insulin independence is achievable through current medical science—at least under controlled research conditions and for select patients. It also shows the potential value of combining existing therapies rather than pursuing single interventions alone.

For people living with Type 1 diabetes, hope grounded in real progress is more meaningful than vague promises. This trial offers both: concrete evidence of a biological possibility, plus honest acknowledgment that translating one patient's success into a practical treatment for many remains an open challenge.

Origin: YouTube / Neil Greathouse (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.